Targeting MET and EGFR in Lung Cancer Treatment
Author Information
Author(s): Tang Z, Du R, Jiang S, Wu C, Barkauskas D S, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern J A, Ma P C
Primary Institution: Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, USA
Hypothesis
MET signalling plays a key role in lung cancer oncogenic signalling and optimised therapy targeting MET would be effective as a treatment strategy in the face of EGFR-TKI resistance.
Conclusion
The study suggests that dual MET and EGFR inhibition may be an effective treatment strategy for overcoming resistance in lung cancer.
Supporting Evidence
- SU11274 significantly induced apoptosis in H1975 cells, which are resistant to erlotinib.
- Dual treatment with SU11274 and erlotinib led to complete regression of H1975 xenografts in vivo.
- MET and EGFR pathways exhibited collaborative signalling in lung cancer cells.
Takeaway
This study found that using two drugs together can help treat lung cancer that doesn't respond to standard treatments. One drug targets MET, and the other targets EGFR.
Methodology
The study used in vitro and in vivo assays to test the effects of MET inhibition on lung cancer cells resistant to EGFR-TKIs.
Statistical Information
P-Value
P=0.0015
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website